跳至主要内容
临床试验/ISRCTN54581790
ISRCTN54581790已完成4 期

Efficacy and safety of Cerebrolysin in the treatment of aphasia after acute ischemic stroke

The foundation for the study of neuroscience and neuroregeneration (SSNN)0 个研究点目标入组 132 人开始时间: 2020年4月29日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
132

研究概览

简要总结

2024 Preprint results in https://doi.org/10.1101/2024.02.23.24303302 (added 19/08/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 04/06/2020:
  • 1. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2. Broca or mixed non-fluent aphasia
  • 3. Inclusion in the study between 3 and 5 days post-stroke
  • 4. Right-handedness
  • 5. Romanian as language of daily use
  • 6. Signed informed consent
  • Previous inclusion criteria:
  • 1. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2. Broca or mixed non-fluent aphasia
  • 3. Inclusion in the study between 5 and 30 days post-stroke
  • 4. Right-handedness
  • 5. Romanian as language of daily use
  • 6. Signed informed consent

排除标准

  • 1. Prior symptomatic ischemic or hemorrhagic stroke
  • 2. Severe comprehension deficit that may compromise informed consent or understanding of instructions such as fluent aphasias (ex. Wernicke aphasia), or global aphasias
  • 3. Contraindications to MRI
  • 4. Preexisting neurodegenerative or psychiatric disease
  • 5. Epilepsy or EEG-documented epileptic discharges
  • 6. Severe chronic renal or liver failure; (AST, ALT > 4 times normal values, creatinine > 4)
  • 7. Life-threatening diseases
  • 8. Auditory or visual deficits that cannot be corrected and might impair testing

研究者

发起方
The foundation for the study of neuroscience and neuroregeneration (SSNN)

相似试验

Can Cerebrolysin improve aphasia after ischemic... | 临床试验